Blueprint Medicines (BPMC) Reports Q3 Loss of $1.93/Share

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.93), versus $1.66 reported last year. Revenue for the quarter came in at $9.14 million, versus $1.1 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Tuya Inc. (TUYA) Reports In-Line Q2 EPS
• Bank of Nova Scotia (BNS) Tops Q2 EPS by 20c